Topical Solution for Verruca Vulgaris Meets Primary and Secondary Efficacy Endpoints

Published Online: Monday, October 28th, 2019
A-101 45% (Aclaris Therapeutics) met the primary and all secondary efficacy endpoints, according to the company. Positive results have been shown for the topical treatment of verruca vulgaris based on data from a second Phase 3 clinical trial, THWART-1 (WART-301).
 
The drug is a proprietary, high-concentration hydrogen peroxide topical solution intended for the treatment of common warts. A-101 was tested for safety and efficacy through two randomized, double-blind trials compared to placebo. 503 participants self-administered either A-101 45% or placebo twice a week over a course of 8 weeks.
 
The primary endpoint was met with statistical significance, with subjects treated with A-101 45% reporting their warts as “clear” at day 60. Warts were assessed using the Physician Wart Assessment™ scale.
 
All secondary efficacy endpoints also achieved statistical significance. The most common adverse events (AEs) occurring in more than 5% of subjects in the A-101 45% group were application site pain, scabbing, erythema, pruritus and erosion. AEs were reported in 52.8% and 6% of the subjects in the A-101 45% and vehicle groups.
 
Reference
 
Aclaris Therapeutics’ A-101 45% topical solution meets primary and all secondary efficacy endpoints in second successful pivotal phase 3 clinical trial for the treatment of common warts (THWART-1) [news release]. Wayne, PA; Aclaris Therapeutics, Inc: October 24, 2019. https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-101-45-topical-solution-meets-primary-and-1. Accessed October 28, 2019.



Current Issue

The Educated Patient

Katarzyna Lalicata, MSN, FNP-C, FNP-BC
The symptoms associated with colds, most commonly congestion, coughing, sneezing, and sore throats, are the body's response when a virus exerts its effects on the immune system. Cold symptoms peak at about 1 to 2 days and last 7 to 10 days but can last up to 3 weeks.
Kristen L. Marjama, DNP, APRN-BC, FNP
Exposure to damp and moly environments may also result in a variety of other health issues.
Bethany Rettberg, NPC
An accurate medical history and a physical exam are critical to rule out more serious conditions.
Bethany Rettberg, NPC
Practitioners should get a detailed medical history and conduct a thorough physical to treat sinus infections.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Advertise
Careers
Contact Us
Feedback
Privacy
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2019
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.